|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,502 GBX | -0.58% |
|
-1.11% | +4.30% |
| 02:19pm | GSK launches antimalarial drug in Thailand and Brazil | CF |
| 01:59pm | Citigroup Trims GSK PT, Maintains Buy Rating | MT |
July 3 (Reuters) - GSK has bought the full rights to develop and manufacture mRNA-based candidate vaccines for influenza and COVID-19 from CureVac for up to 1.05 billion euros ($1.13 billion), it said on Wednesday.
GSK and CureVac started collaborating in 2020 to develop mRNA-based vaccines for infectious diseases. ($1 = 0.9313 euros) (Reporting by Yadarisa Shabong in Bengaluru; Editing by Savio D'Souza)
| 1st Jan change | Capi. | |
|---|---|---|
| +4.30% | 78.64B | |
| +55.82% | 809B | |
| +39.46% | 624B | |
| -7.66% | 351B | |
| +6.14% | 289B | |
| +13.22% | 240B | |
| +13.76% | 220B | |
| -0.45% | 219B | |
| +7.53% | 166B | |
| -3.32% | 157B |
GSK PLC 
